Press Release

Chengdu, China, December 9th, 2019 – HitGen Inc. (“HitGen”) is pleased to announce that the company has entered into a strategic collaboration with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to design and build novel DNA-encoded libraries (“DELs”) to discover unique small molecule assets. The collaboration will apply HitGen’s advanced technology platform and research capabilities in the design and synthesis of multiple proprietary DELs for Janssen drug discovery and development efforts.The collaboration was facilitated by Johnson & Johnson Innovation and builds upon the success of earlier agreements for the identification of hits using HitGen’s platform for various priority targets.

Ballerup, Denmark and Chengdu, China, November 12, 2019 – LEO Pharma A/S and HitGen Inc. are pleased to announce that HitGen and LEO Pharma expands their collaboration with a license to develop a novel class of drugs for a dermatology indication.

Chengdu, China,October 16th,2019 – HitGen Inc. today announced that it has entered into a drug discovery research collaboration with Galapagos NV to identify potential small molecule leads against targets of interest to Galapagos NV.In this collaboration,HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads. Under the terms of the agreement,HitGen will receive an undisclosed upfront payment and will be eligible for milestone payments from Galapagos NV.

Chengdu, China，June 3rd, 2019-HitGen Inc today announced that it has entered into adrug discovery research collaboration with Gilead Sciences to identify potential small molecule leads against targets of interest to Gilead.In this collaboration,HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads. Under the terms of the agreement,HitGen will receive an undisclosed upfront payment and will be eligible formilestone payments from Gilead.

Kenilworth, N.J., U.S.A. CHENGDU, CHINA – April 18, 2019, HitGen Inc., announced today that it has achieved a milestone in its discovery alliance with Merck & Co. Inc., Kenilworth NJ, USA, known as MSD outside the United States and Canada. The milestone was for the identification of candidates meeting pre-defined criteria, representing the 3rd discovery program between the two companies for which HitGen has achieved this milestone. This achievement entitles HitGen to receive an undisclosed payment per the research collaboration agreement between both companies announced March 14, 2017.

Chengdu, China, April 11, 2019 HitGen Inc. announced today that HitGen Inc. and Kaken Pharmaceutical Co., Ltd. have entered into a license agreement to develop a novel class of drugs. The licensed compounds were identified using HitGen’s leading technology platform, which involved screening large DNA encoded libraries, containing over 400 billion of small molecules with drug-like properties synthesized on chemically diverse scaffolds. A number of novel small molecule leads for an undisclosed target nominated by Kaken were the subject of this license agreement.

Chengdu, China, March 25, 2019, HitGen Ltd announced that the company has entered into a research collaboration with Almirall to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for Almirall. Under the terms of the agreement, HitGen will receive upfront payments, and be eligible for milestone payments from Almirall. Specific financial details were not disclosed.

CHENGDU and MUMBAI –March 13, 2019,HitGenLtd. and Sun Pharma Advanced Research Company Ltd. (SPARC)(Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) todayannounced a research collaboration toidentifynovel small molecule leads for targets of interest.Under this collaboration,HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads forSPARC. Under the terms of the agreement,HitGenwill receive upfrontpaymentand will be eligible for certainmilestone payments.

Chengdu, China, December 20, 2018, HitGen Ltd announced that the company has entered into a research collaboration with the Crop Science division of Bayer to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for Bayer research endeavours. Under the terms of the agreement, HitGen will receive upfront payments, and be eligible for milestone payments from Bayer. Specific financial details were not disclosed.

Chengdu, China, December 11, 2018, HitGen Ltd announced that the company has entered into a drug discovery research collaboration with Mitsubishi Tanabe Pharma Corporation (President and CEO: Masayuki Mitsuka; Headquarters: Osaka; “MTPC”) to identify novel small molecule leads for targets of interest. According to the agreement, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis, and screening system, to discover novel lead compounds. The collaboration will use HitGen’s libraries containing more than 300 billion individually DNA-encoded compounds. The DNA encoding of molecules enables screening and analysis of vast chemical space, supporting MTPC’s aim to increase success rates for the generation of target leads for new drugs and to drastically shorten screening timelines for expanding MTPC’s pipeline. Under the terms of the agreement, HitGen will receive technology access and research support payments, and be eligible for milestone payments from MTPC. Financial details were not disclosed.